10-Q: Aimfinity Faces Going Concern, Trust Shrinks Ahead of Docter Merger

Aimfinity Investment Corp. I reported a substantial decrease in its trust account due to significant shareholder redemptions, extended its business combination deadline with Docter Inc. to October 28, 2025, and disclosed management's doubt about its ability to continue as a going concern.

Summary

• The Trust Account balance significantly decreased to $13,981,534 as of June 30, 2025, from $36,940,228 at December 31, 2024, primarily due to shareholder redemptions.
• Shareholder redemptions totaled $23,778,577 for 1,996,522 Class A ordinary shares following the extraordinary general meeting on January 9, 2025.
• The deadline to complete an initial business combination with Docter Inc. has been extended multiple times, with the current deadline set for October 28, 2025, through monthly extensions funded by the Sponsor.
• Management has raised substantial doubt about the Company's ability to continue as a going concern due to insufficient cash and working capital to complete the business combination.
• Net income for the six months ended June 30, 2025, was $75,425, a significant decrease from $877,374 for the same period in 2024.
• Formation and operating costs increased to $409,516 for the six months ended June 30, 2025, from $261,216 in the prior year period.
• The deferred underwriting commission of $2,817,500 will be settled with $160,000 in cash and 265,750 Purchaser Ordinary Shares at the closing of the business combination.

Sentiment

Score: 2

Explanation: The company faces severe challenges, including a drastically reduced trust account, significant shareholder redemptions, a substantial working capital deficit, and management's explicit doubt about its ability to continue as a going concern. While the merger deadline was extended and underwriters agreed to equity settlement, the overall financial health and operational uncertainty are highly negative.

Positives

• Successfully extended the business combination deadline to October 28, 2025, providing more time to close the Docter Inc. merger.
• Underwriters agreed to accept a combination of cash ($160,000 total) and Purchaser Ordinary Shares (265,750 total) in lieu of the full $2,817,500 deferred underwriting commission, reducing immediate cash outflow.
• Net cash used in operating activities improved to $(217,947) for the six months ended June 30, 2025, compared to $(389,950) in the prior year period.
• Total liabilities decreased to $5,337,423 as of June 30, 2025, from $6,092,965 at December 31, 2024.
• Total Shareholders Deficit improved to $(5,332,528) as of June 30, 2025, from $(6,088,070) at December 31, 2024, primarily due to the conversion of related party loans into equity.

Negatives

• The Trust Account balance decreased significantly by over 62% from $36,940,228 to $13,981,534, primarily due to substantial shareholder redemptions.
• Net income for the six months ended June 30, 2025, plummeted to $75,425 from $877,374 in the same period last year, a decrease of approximately 91%.
• Formation and operating costs increased to $409,516 for the six months ended June 30, 2025, from $261,216 in the prior year period.
• The Company has a working capital deficit of $2,515,028 as of June 30, 2025.
• Interest earned on cash and investments in the Trust Account decreased significantly to $484,941 for the six months ended June 30, 2025, from $1,138,590 in the prior year period.
• Accumulated deficit worsened to $(6,832,778) as of June 30, 2025, from $(6,088,320) at December 31, 2024.

Risks

• Substantial doubt about the Company's ability to continue as a going concern due to insufficient cash and working capital to complete the initial business combination by the October 28, 2025 deadline.
• Risk of liquidation if the initial business combination with Docter Inc. is not consummated by the Combination Deadline, which would extinguish public shareholders' rights.
• The Company's disclosure controls and procedures were deemed not effective as of June 30, 2025.
• Geopolitical events, such as the military action in Ukraine and related economic sanctions, may materially and adversely affect the ability to consummate an initial business combination or the operations of a target business, including impacting equity and debt financing availability.

Future Outlook

The Company's primary focus is to consummate the business combination with Docter Inc. by the extended deadline of October 28, 2025. Future share issuances to Docter stockholders are contingent on achieving device sales targets of 30,000 units in fiscal year 2025 and 40,000 units in fiscal year 2026. The Company faces significant uncertainty regarding its ability to continue as a going concern if the merger is not completed, which could lead to liquidation.

Management Comments

• "Management has determined that these conditions [insufficient cash and working capital, risk of not completing business combination] raise substantial doubt about the Company's ability to continue as a going concern."
• "Our Chief Executive Officer and General Counsel concluded that our disclosure controls and procedures (as defined in Rules 13a-15 (e) and 15d-15 (e) under the Exchange Act) were not effective."

Industry Context

The SPAC market has seen increased redemptions and challenges in completing business combinations, particularly as deadlines approach. Aimfinity's situation reflects broader trends of SPACs struggling to find suitable targets or retain investor capital, leading to reduced trust account balances and heightened going concern risks. The conversion of deferred underwriting fees into equity is also a a common strategy for SPACs facing liquidity constraints.

Management Changes

Corporate Governance

Related Party Transactions

• Working Capital Loans from I-Fa Chang (Sponsor's manager/designee) totaling $1,393,270 outstanding as of June 30, 2025.
• Extension Loans from I-Fa Chang totaling $167,471 outstanding as of June 30, 2025.
• Conversion of $1,500,000 of outstanding promissory notes (from I-Fa Chang) into 150,000 private units on April 8, 2025.
• Acquisition of Inkrock Holding Limited from I-Fa Chang by PubCo for 687,054 ordinary shares, initially agreed on May 27, 2025, terminated on October 6, 2025, and re-agreed on October 7, 2025, to occur upon Business Combination closing.
• Sponsor (Aimfinity Investment LLC) acquired 2,875,000 founder shares for $25,000 on December 4, 2021, and later surrendered 862,500 shares.
• Sponsor transferred 20,000 founder shares to the CFO and 60,000 to certain board members on March 29, 2022.
• I-Fa Chang sold membership interests in the Sponsor to Mr. Chun-Cheng Su and Mr. Xuedong (Tony) Tian on January 19, 2024.

Stakeholder Impact

• Shareholders: Significant redemptions have reduced the value of the trust account per share. Remaining public shareholders face substantial risk of liquidation if the business combination is not completed by October 28, 2025, potentially extinguishing their rights.
• Sponsor (Aimfinity Investment LLC) and I-Fa Chang: Have provided significant loans to fund extensions and working capital, some of which have been converted into private units, indicating continued commitment but also exposure to the Company's going concern risk.
• Docter Inc. Stockholders: Stand to receive earnout shares contingent on future device sales performance of PubCo, aligning their interests with the combined entity's operational success.
• Underwriters (D. Boral Capital LLC and US Tiger Securities, Inc.): Agreed to receive a reduced cash payment and equity in PubCo for their deferred underwriting commission, indicating a willingness to support the merger's completion.

Next Steps

• Consummate the initial business combination with Docter Inc. by October 28, 2025.
• PubCo must achieve sales of at least 30,000 Devices during fiscal year 2025 for the first earnout tranche of 1,000,000 shares to Docter Stockholders.
• PubCo must achieve sales of at least 40,000 Devices during fiscal year 2026 for the second earnout tranche of 1,500,000 shares to Docter Stockholders.
• Address the identified ineffective disclosure controls and procedures.

Key Dates

Recommendation

The company is a SPAC with a rapidly depleting trust account due to massive shareholder redemptions, a significant working capital deficit, and management's explicit declaration of substantial doubt about its ability to continue as a going concern. The extended deadline to complete the merger with Docter Inc. is imminent (October 28, 2025), and failure to close will result in liquidation, extinguishing public shareholders' rights. The financial results show a sharp decline in net income and interest earned, coupled with rising operating costs. These factors present an extremely high-risk profile with a strong likelihood of capital loss for current shareholders.

Keywords

SPAC, Blank Check Company, Docter Inc., Merger Agreement, Shareholder Redemptions, Trust Account, Going Concern, SEC Filing, Quarterly Report, Corporate Governance, Related Party Transactions, Warrants, IPO